Amylyx Pharmaceuticals Etf Profile
| AMLX Etf | USD 1.88 0.07 3.59% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Amylyx Pharmaceuticals is trading at 1.88 as of the 24th of April 2024; that is -3.59 percent decrease since the beginning of the trading day. The etf's open price was 1.95. Amylyx Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Amylyx Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of January 2022 | Category Healthcare | Classification Health Care |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.. The company has 67.78 M outstanding shares of which 6.01 M shares are presently shorted by private and institutional investors with about 0.99 trading days to cover. More on Amylyx Pharmaceuticals
Moving together with Amylyx Etf
| 0.8 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.69 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Amylyx Etf
| 0.87 | YS | YS Biopharma | PairCorr |
| 0.72 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.7 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.66 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.66 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.6 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.49 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
Amylyx Etf Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Amylyx Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Amylyx Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering Amylyx Pharmaceuticals report their recommendations after researching Amylyx Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Amylyx Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Amylyx Pharmaceuticals. The Amylyx consensus assessment is calculated by taking the average forecast from all of the analysts covering Amylyx Pharmaceuticals. | |
| Tax Provision | 5.03 Million |
| Logo U R L | imglogosUSAMLX.png |
| Total Current Liabilities | 82.04 Million |
| Total Stockholder Equity | 433.43 Million |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 37.16 Million |
| Property Plant And Equipment Net | 6.41 Million |
| Begin Period Cash Flow | 63.24 Million |
| Net Debt | (165.96 Million) |
| Accounts Payable | 22.06 Million |
| Cash | 170.2 Million |
| Other Operating Expenses | 341.98 Million |
| Non Current Assets Total | 52.79 Million |
| Non Currrent Assets Other | 45.66 Million |
| Forward Price Earnings | 2.7739 |
| Cash And Short Term Investments | 371.36 Million |
| 50 Day M A | 8.2618 |
| Code | AMLX |
| Common Stock Shares Outstanding | 69.99 Million |
| Liabilities And Stockholders Equity | 517.45 Million |
| Country Name | USA |
| Net Interest Income | 16.16 Million |
| Capital Lease Obligations | 4.24 Million |
| E P S Estimate Next Year | (0.77) |
| Investments | (157.05 Million) |
| Other Current Assets | 14.93 Million |
| Total Liab | 84.02 Million |
| Free Cash Flow | 10.68 Million |
| Net Invested Capital | 433.43 Million |
Amylyx Pharmaceuticals [AMLX] is traded in USA and was established 2018-03-26. Amylyx Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The fund is listed under Health Care category and is part of Pharmaceuticals family. Amylyx Pharmaceuticals presently have 517.45 M in assets under management (AUM).
Amylyx Pharmaceuticals currently holds about 206.68 M in cash with 11.92 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Amylyx Pharmaceuticals Probability Of Bankruptcy
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Amylyx Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Amylyx Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Amylyx Pharmaceuticals Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Top Amylyx Pharmaceuticals Etf Constituents
| WES | Western Midstream Partners | Stock | Energy |
| VNOM | Viper Energy Ut | Stock | Energy |
| GEL | Genesis Energy LP | Stock | Energy |
| NGL | NGL Energy Partners | Stock | Energy |
| PAGP | Plains GP Holdings | Stock | Energy |
| MPLX | MPLX LP | Stock | Energy |
| NS | NuStar Energy LP | Stock | Energy |
Amylyx Pharmaceuticals Target Price Odds Analysis
Based on a normal probability distribution, the odds of Amylyx Pharmaceuticals jumping above the current price in 90 days from now is about 86.81%. The Amylyx Pharmaceuticals probability density function shows the probability of Amylyx Pharmaceuticals etf to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the etf has a beta coefficient of 4.572. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Amylyx Pharmaceuticals will likely underperform. Additionally, amylyx Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Amylyx Pharmaceuticals to move above the current price in 90 days from now is about 86.81 (This Amylyx Pharmaceuticals probability density function shows the probability of Amylyx Etf to fall within a particular range of prices over 90 days) .
Amylyx Pharmaceuticals Major Institutional Holders
Institutional Holdings refers to the ownership stake in Amylyx Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amylyx Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amylyx Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Nantahala Capital Management, Llc | 2023-12-31 | 1.2 M | |
| Citadel Advisors Llc | 2023-09-30 | 1.2 M | |
| Jane Street Group, Llc | 2023-12-31 | 1.2 M | |
| Eventide Asset Management, Llc | 2023-12-31 | 1.1 M | |
| Saturn V Capital Management Llc | 2023-12-31 | 1.1 M | |
| Jupiter Asset Management Limited | 2023-12-31 | 1.1 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1 M | |
| Nuveen Asset Management, Llc | 2023-12-31 | 1 M | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 985.1 K | |
| Vanguard Group Inc | 2023-12-31 | 5.3 M | |
| Blackrock Inc | 2023-12-31 | 4 M |
Amylyx Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Amylyx Pharmaceuticals market risk premium is the additional return an investor will receive from holding Amylyx Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Amylyx Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Amylyx Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Amylyx Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (1.99) | |||
| Total Risk Alpha | (3.15) | |||
| Treynor Ratio | (0.35) |
Amylyx Pharmaceuticals Against Markets
Picking the right benchmark for Amylyx Pharmaceuticals etf is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Amylyx Pharmaceuticals etf price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Amylyx Pharmaceuticals is critical whether you are bullish or bearish towards Amylyx Pharmaceuticals at a given time. Please also check how Amylyx Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Amylyx Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
How to buy Amylyx Etf?
Before investing in Amylyx Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Amylyx Pharmaceuticals. To buy Amylyx Pharmaceuticals etf, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Amylyx Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Amylyx Pharmaceuticals etf. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Amylyx Pharmaceuticals etf in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Amylyx Pharmaceuticals etf, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the etf
It's important to note that investing in stocks, such as Amylyx Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in etf prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Amylyx Pharmaceuticals?
The danger of trading Amylyx Pharmaceuticals is mainly related to its market volatility and ETF specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amylyx Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amylyx Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amylyx Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amylyx Pharmaceuticals. Also, note that the market value of any etf could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Amylyx Etf please use our How to Invest in Amylyx Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
The market value of Amylyx Pharmaceuticals is measured differently than its book value, which is the value of Amylyx that is recorded on the company's balance sheet. Investors also form their own opinion of Amylyx Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Amylyx Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amylyx Pharmaceuticals' market value can be influenced by many factors that don't directly affect Amylyx Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amylyx Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amylyx Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amylyx Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.